EGFR TKIs impair lysosome-dependent degradation of SQSTM1 to compromise the effectiveness in lung cancer

Tyrosine kinase inhibitors for epidermal growth factor receptor (EGFR TKIs) greatly improved clinical outcomes of patients with non-small cell lung cancer (NSCLC). Unfortunately, primary and acquired resistance limits their clinical benefits. To overcome such resistance, new generations of EGFR TKIs...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Lixian, Ying, Shilong, Hu, Shiman, Zhao, Xiangtong, Li, Muchun, Chen, Miaoqin, Zhu, Yiran, Song, Ping, Zhu, Liyuan, Jiang, Tingting, An, Huimin, Yousafzai, Neelum Aziz, Xu, Wenxia, Zhang, Zhiguo, Wang, Xian, Feng, Lifeng, Jin, Hongchuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6799834/
https://www.ncbi.nlm.nih.gov/pubmed/31637005
http://dx.doi.org/10.1038/s41392-019-0059-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6799834/
https://www.ncbi.nlm.nih.gov/pubmed/31637005
http://dx.doi.org/10.1038/s41392-019-0059-4

Ejemplares similares